StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen LUMAKRAS / LUMYKRAS (sotorasib by Year

LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

Amgen LUMAKRAS / LUMYKRAS (sotorasib: $363M in FY2025, up 3.7% from a year earlier.

Latest, FY2025
363
Period ended Dec 31, 2025
Change on a year earlier
+3.7%
350 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below

Where the FY2025 figure comes from

“|| LUMAKRAS ® /LUMYKRAS ™ | 211 | 152 | 363 | 350 | 4%”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025363+3.7%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024350+25.0%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023280-1.8%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
FY2022Dec 31, 2022285+216.7%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
FY2021Dec 31, 202190–Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗

Breakdown

What makes up LUMAKRAS / LUMYKRAS (sotorasib

Cite this data

StockData. (2026). Amgen LUMAKRAS / LUMYKRAS (sotorasib ($M), annual FY2021–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-lumakras-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.